GRI Bio, Inc. announced on June 18, 2026, that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to GRI-0621 for treating idiopathic pulmonary fibrosis. GRI Bio, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.
